Literature DB >> 27117052

Endoscopic treatment of grades IV and V vesicoureteral reflux with two bulking substances: Dextranomer hyaluronic acid copolymer versus polyacrylate polyalcohol copolymer in children.

Canan Kocaoglu1.   

Abstract

PURPOSE: We aimed at evaluating the efficacy and complications of two bulking substances: dextranomer/hyaluronic acid copolymer(Dx/Ha;Dexell®) versus polyacrylate polyalcohol copolymer(PPC;Vantris®) in subureteric injection treatment of children with high grades (grades IV-V) vesicoureteral reflux(VUR).
METHODS: Data of patients undergoing endoscopic treatment of high grade VUR (January 2009-August 2015) were retrospectively investigated. Patients with high grade VUR caused by posterior urethral valve, duplex system, paraureteral diverticula and neurogenic bladder were excluded. Classical subureteric injection method (STING) was used. Seventy-three children (45 girls and 28 boys) who had 88 refluxing renal units (RRUs) with grades IV-V VUR (n=64/n=24) underwent endoscopic treatment using Dx/Ha (n=63 RRUs) and PPC (n=25 RRUs).
RESULTS: Mean age of patients in Dx/Ha and PPC groups were 6 (3) and 6 (3.75) year (p=0.81), and volumes of these substances given were 1.3 (1) and 1 (0.5) mL (p=0.003), respectively. Overall, for the first endoscopic injection, success rate of grades IV-V VUR per RRU was 53.9% with Dx/Ha, compared to 80% in PPC-injected group, (p=0.024). Late ureterovesical junction obstruction developed only in one patient in PPC-injected group. No ureteral obstruction was observed in Dx/Ha-injected group.
CONCLUSIONS: Endoscopic injection of PPC resulted in significantly higher success rate, compared to Dx/Ha in subureteric injection treatment of children with high grade VUR. However, the development of late ureterovesical junction obstruction should also be taken into account in PPC injection.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dexell; Dextranomer/hyaluronic acid copolymer; Endoscopic injection; High grade vesicoureteral reflux; Polyacrylate polyalcohol copolymer; Vantris

Mesh:

Substances:

Year:  2016        PMID: 27117052     DOI: 10.1016/j.jpedsurg.2016.03.013

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  7 in total

Review 1.  Vesicoureteral reflux: From prophylaxis to surgery.

Authors:  Anne-Sophie Blais; Stéphane Bolduc; Katherine Moore
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

2.  Randomized clinical trial between polyacrylate-polyalcohol copolymer (PPC) and dextranomer-hyaluronic acid copolymer (Dx/HA) as bulking agents for endoscopic treatment of primary vesicoureteral reflux (VUR).

Authors:  L García-Aparicio; E Blázquez-Gómez; O Martin; S Pérez-Bertólez; J Arboleda; A Soria; X Tarrado
Journal:  World J Urol       Date:  2018-05-03       Impact factor: 4.226

3.  Macroplastique and Botox are superior to Macroplastique alone in the management of neurogenic vesicoureteric reflux in spinal cord injury population with presumed healthy bladders.

Authors:  Vasileios I Sakalis; Rachel Oliver; Peter J Guy; Melissa C Davies
Journal:  J Spinal Cord Med       Date:  2018-02-07       Impact factor: 1.985

Review 4.  Endoscopic injection therapy.

Authors:  Sang Woon Kim; Yong Seung Lee; Sang Won Han
Journal:  Investig Clin Urol       Date:  2017-06-02

5.  The learning curve of sting method for endoscopic injection treatment of vesicoureteral reflux.

Authors:  Ayhan Dalkiliç; Göksel Bayar; Hasan Demirkan; Kaya Horasanli
Journal:  Int Braz J Urol       Date:  2018 Nov-Dec       Impact factor: 1.541

6.  New bulking agent for the treatment of vesicoureteral reflux: Polymethylmethacrylate/dextranomer.

Authors:  Sang Woon Kim; Yong Seung Lee; Young Jae Im; Sang Won Han
Journal:  Investig Clin Urol       Date:  2018-04-10

7.  Endoscopic correction of vesicoureteral reflux in children using polyacrylate-polyalcohol copolymer (Vantris): 5-years of prospective follow-up.

Authors:  Stanisław Warchoł; Grażyna Krzemień; Agnieszka Szmigielska; Przemysław Bombiński; Krzysztof Toth; Teresa Dudek-Warchoł
Journal:  Cent European J Urol       Date:  2017-07-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.